BACKGROUND: Myocyte death occurs by necrosis and caspase-mediated apoptosis in myocardial infarction (MI). In vitro studies suggest caspase activation causes myocardial contractile protein degradation without inducing apoptosis. Thus, caspase activation may evoke left ventricular (LV) remodeling through independent processes post-MI. The effects of caspase activation on LV geometry post-MI remain unclear. This project applied pharmacologic caspase inhibition (CASPI) to a porcine model of MI. METHODS AND RESULTS: Pigs (34 kg) were instrumented to induce 60 minutes of coronary artery occlusion followed by reperfusion and a 7-day follow-up period. Upon reperfusion, the pigs were randomized to saline (n = 12) or CASPI (n = 10, IDN6734, 6 mg/kg i.v., then 6 mg/kg/h for 24 hours). Plasma troponin-I values were reduced with CASPI compared with saline at 24 hours post-MI (133 +/- 15 vs. 189 +/- 20 ng/mL, respectively, P < 0.05). LV end-diastolic area (echocardiography) and interregional length (sonomicrometry) increased from baseline in both groups but were attenuated with CASPI by 40% and 90%, respectively (P < 0.05). Myocyte length was reduced with CASPI compared with saline (128 +/- 3 vs. 141 +/- 4 microm, respectively, P < 0.05). Plasma-free pro-matrix metalloproteinase-2 values increased from baseline with CASPI (27% +/- 6%, P < 0.05) indicative of reduced conversion to active MMP-2. Separate in vitro studies demonstrated that activated caspase species cleaved pro-MMP-2 yielding active MMP-2 forms and that MMP activity was increased in the presence of activated caspase-3. CONCLUSIONS: CASPI attenuated regional and global LV remodeling post-MI and altered viable myocyte geometry. Caspases increased MMP activity in vitro, whereas CASPI modified conversion of MMP-2 to the active form in vivo. Taken together, the results of the present study suggest that the elaboration of caspases post-MI likely contribute to LV remodeling through both cellular and extracellular mechanisms.
BACKGROUND: Myocyte death occurs by necrosis and caspase-mediated apoptosis in myocardial infarction (MI). In vitro studies suggest caspase activation causes myocardial contractile protein degradation without inducing apoptosis. Thus, caspase activation may evoke left ventricular (LV) remodeling through independent processes post-MI. The effects of caspase activation on LV geometry post-MI remain unclear. This project applied pharmacologic caspase inhibition (CASPI) to a porcine model of MI. METHODS AND RESULTS:Pigs (34 kg) were instrumented to induce 60 minutes of coronary artery occlusion followed by reperfusion and a 7-day follow-up period. Upon reperfusion, the pigs were randomized to saline (n = 12) or CASPI (n = 10, IDN6734, 6 mg/kg i.v., then 6 mg/kg/h for 24 hours). Plasma troponin-I values were reduced with CASPI compared with saline at 24 hours post-MI (133 +/- 15 vs. 189 +/- 20 ng/mL, respectively, P < 0.05). LV end-diastolic area (echocardiography) and interregional length (sonomicrometry) increased from baseline in both groups but were attenuated with CASPI by 40% and 90%, respectively (P < 0.05). Myocyte length was reduced with CASPI compared with saline (128 +/- 3 vs. 141 +/- 4 microm, respectively, P < 0.05). Plasma-free pro-matrix metalloproteinase-2 values increased from baseline with CASPI (27% +/- 6%, P < 0.05) indicative of reduced conversion to active MMP-2. Separate in vitro studies demonstrated that activated caspase species cleaved pro-MMP-2 yielding active MMP-2 forms and that MMP activity was increased in the presence of activated caspase-3. CONCLUSIONS:CASPI attenuated regional and global LV remodeling post-MI and altered viable myocyte geometry. Caspases increased MMP activity in vitro, whereas CASPI modified conversion of MMP-2 to the active form in vivo. Taken together, the results of the present study suggest that the elaboration of caspases post-MI likely contribute to LV remodeling through both cellular and extracellular mechanisms.
Authors: T Etoh; C Joffs; A M Deschamps; J Davis; K Dowdy; J Hendrick; S Baicu; R Mukherjee; M Manhaini; F G Spinale Journal: Am J Physiol Heart Circ Physiol Date: 2001-09 Impact factor: 4.733
Authors: C Joffs; H R Gunasinghe; M M Multani; B H Dorman; J M Kratz; A J Crumbley; F A Crawford; F G Spinale Journal: Ann Thorac Surg Date: 2001-05 Impact factor: 4.330
Authors: S Minatoguchi; T Kariya; Y Uno; M Arai; Y Nishida; K Hashimoto; N Wang; T Aoyama; G Takemura; T Fujiwara; H Fujiwara Journal: Jpn Circ J Date: 2001-10
Authors: A Ducharme; S Frantz; M Aikawa; E Rabkin; M Lindsey; L E Rohde; F J Schoen; R A Kelly; Z Werb; P Libby; R T Lee Journal: J Clin Invest Date: 2000-07 Impact factor: 14.808
Authors: T Okamura; T Miura; G Takemura; H Fujiwara; H Iwamoto; S Kawamura; M Kimura; Y Ikeda; M Iwatate; M Matsuzaki Journal: Cardiovasc Res Date: 2000-02 Impact factor: 10.787
Authors: J H McElmurray; R Mukherjee; R B New; A C Sampson; M K King; J W Hendrick; A Goldberg; T J Peterson; H Hallak; M R Zile; F G Spinale Journal: J Pharmacol Exp Ther Date: 1999-11 Impact factor: 4.030
Authors: P Kovacs; I Bak; L Szendrei; M Vecsernyes; E Varga; I E Blasig; A Tosaki Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2001-12 Impact factor: 3.000
Authors: Misun Park; You-Tang Shen; Vinciane Gaussin; Guy R Heyndrickx; Jozef Bartunek; Ranillo R G Resuello; Filipinas F Natividad; Richard N Kitsis; Dorothy E Vatner; Stephen F Vatner Journal: Am J Physiol Heart Circ Physiol Date: 2009-05-22 Impact factor: 4.733
Authors: Douwe de Boer; Alexander S Streng; William P T M van Doorn; Wim H M Vroemen; Otto Bekers; Will K W H Wodzig; Alma M A Mingels Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622